Citadel Advisors
KYMR icon

Citadel Advisors’s Kymera Therapeutics KYMR Stock Holding History

Citadel Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.88M Sell
118,597
-41,268
-26% -$3.27M ﹤0.01% 3274
2025
Q4 		$12.4M Buy
159,865
+118,042
+282% +$7.97M ﹤0.01% 2966
2025
Q3 		$2.37M Sell
41,823
-477,064
-92% -$21.5M ﹤0.01% 5724
2025
Q2 		$22.6M Buy
518,887
+516,382
+20,614% +$17.8M ﹤0.01% 2003
2025
Q1 		$68.6K Sell
2,505
-56,062
-96% -$2.04M ﹤0.01% 11944
2024
Q4 		$2.36M Sell
58,567
-2,765
-5% -$125K ﹤0.01% 5292
2024
Q3 		$2.9M Sell
61,332
-92,325
-60% -$4.08M ﹤0.01% 4846
2024
Q2 		$4.59M Sell
153,657
-107,724
-41% -$3.73M ﹤0.01% 3888
2024
Q1 		$10.5M Sell
261,381
-110,062
-30% -$3.94M ﹤0.01% 2891
2023
Q4 		$9.46M Buy
371,443
+152,460
+70% +$2.73M ﹤0.01% 2923
2023
Q3 		$3.04M Sell
218,983
-60,599
-22% -$1.22M ﹤0.01% 4458
2023
Q2 		$6.43M Buy
279,582
+279,364
+128,149% +$8M ﹤0.01% 3272
2023
Q1 		$6.46K Sell
218
-27,791
-99% -$896K ﹤0.01% 13803
2022
Q4 		$699K Sell
28,009
-23,610
-46% -$630K ﹤0.01% 7545
2022
Q3 		$1.12M Buy
+51,619
New +$1.36M ﹤0.01% 6736
2022
Q2 		– Sell
-74,658
Closed -$1.74M – 13547
2022
Q1 		$3.16M Buy
74,658
+40,860
+121% +$1.73M ﹤0.01% 5060
2021
Q4 		$2.15M Sell
33,798
-80,130
-70% -$4.67M ﹤0.01% 6074
2021
Q3 		$6.69M Buy
113,928
+51,440
+82% +$2.98M ﹤0.01% 3755
2021
Q2 		$3.03M Sell
62,488
-62,237
-50% -$2.7M ﹤0.01% 5575
2021
Q1 		$4.85M Buy
+124,725
New +$7.51M ﹤0.01% 4319

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citadel Advisors's KYMR Position: Q1 2026 in Review

Citadel Advisors reduced its Kymera Therapeutics (KYMR) stake by 26% in Q1 2026, selling an estimated $3.27M and leaving 118,597 shares worth $9.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3274.

Citadel Advisors first reported a position in KYMR in Q1 2021 and has held it in 20 quarters since. The position peaked at $22.6M in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Citadel Advisors held 118,597 shares of Kymera Therapeutics worth $9.88M as of Q1 2026.
  • Citadel Advisors sold 41,268 Kymera Therapeutics shares in Q1 2026, an estimated $3.27M.
  • Kymera Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3274 holding.
  • Citadel Advisors first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Kymera Therapeutics position peaked at $22.6M in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.